2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed TreatmentDisease course
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsThe Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis
Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal Of Urology 2021, 206: 507-516. PMID: 33904755, DOI: 10.1097/ju.0000000000001821.Peer-Reviewed Original ResearchConceptsRisk of BCRPI-RADS v2 scoreDefinitive local therapyBiochemical recurrencePrognostic significanceRadical prostatectomyProstate cancerV2 scoreLocal therapySystematic reviewMagnetic resonance imaging (MRI) classificationPrimary definitive treatmentIndependent prognostic significanceRisk of biasSignificant prostate cancerProstate Imaging ReportingPI-RADS v2Prostate cancer diagnosisWeb of ScienceReliable diagnostic toolOncologic outcomesDefinitive treatmentMRI findingsPI-RADSPrognostic association
2020
Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
Hafez N, Gettinger S. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective. The Cancer Journal 2020, 26: 144-148. PMID: 32205539, DOI: 10.1097/ppo.0000000000000439.Peer-Reviewed Original ResearchConceptsAggressive local therapySubset of patientsLocal therapyOligometastatic diseaseCancer patientsNon-small cell lung cancer patientsOligometastatic colorectal cancer (CRC) patientsCell lung cancer patientsLong-term disease remissionStereotactic body radiation therapyLimited nodal involvementMedical oncology perspectiveDefinitive local therapyColorectal cancer patientsSolid tumor patientsLung cancer patientsSolid tumor malignanciesBody radiation therapyDisease remissionOligometastatic statePrimary therapyNodal involvementOverall survivalSystemic therapyMetastatic sites
2015
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease
Tsao C, Gray K, Nakabayashi M, Evan C, Kantoff P, Huang J, Galsky M, Pomerantz M, Oh W. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. Journal Of Urology 2015, 194: 91-97. PMID: 25623747, DOI: 10.1016/j.juro.2015.01.078.Peer-Reviewed Original ResearchConceptsDefinitive local therapyGleason 8 diseaseGleason score 8Gleason 9Increased risk of deathRadiation therapyLocal therapyRisk of deathIncreased riskGleason 8Radical prostatectomyScore 8Associated with higher prostate specific antigenPatients treated with radical prostatectomyBiopsy Gleason score 8Gleason 9-10 diseaseHigher prostate specific antigenNeoadjuvant/adjuvant androgen deprivation therapyAndrogen deprivation therapyHigh grade diseaseBaseline patient characteristicsProstate specific antigenMultivariate Cox modelMedian followupBiochemical recurrence
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapy
2011
Endocrine therapy for prostate cancer: review of the latest clinical evidence
Tsao C, Seng S, Oh W, Galsky M. Endocrine therapy for prostate cancer: review of the latest clinical evidence. Clinical Investigation 2011, 1: 533-541. DOI: 10.4155/cli.11.28.Peer-Reviewed Original ResearchProstate cancerEndocrine therapyAdvent of prostate-specific antigen screeningTreatment of castration-resistant prostate cancerCastration-resistant prostate cancerProstate-specific antigen screeningCombined hormone therapyComplete androgen blockadeDefinitive local therapyAndrogen blockadeCastration resistanceAndrogen deprivationAndrogen resistanceLocal therapyHormone therapyLocalized diseaseNonskin cancerAntigen screeningClinical evidenceResponse rateTherapyCancerProstateBlockadeRecurrence
2010
Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?
Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? Annals Of Surgical Oncology 2010, 18: 733-737. PMID: 20882415, DOI: 10.1245/s10434-010-1366-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBreast NeoplasmsChemotherapy, AdjuvantCisplatinCombined Modality TherapyFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPostoperative ComplicationsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSentinel Lymph Node BiopsySurvival RateTreatment OutcomeConceptsTriple-negative breast cancerSingle-arm trialNeoadjuvant cisplatinPostoperative complicationsBreast cancerTwo-sided Fisher's exact testExpander/implantsSafety of bevacizumabOperable breast cancerDefinitive local therapyBreast cancer surgeryNegative breast cancerFisher's exact testBackgroundNeoadjuvant chemotherapyNeoadjuvant settingNeoadjuvant therapyProtocol therapySurgical complicationsLocal therapyRelated complicationsCancer surgeryCisplatin therapyBreast surgeryComplicationsPatients
2009
Surgical Complications and the Use of Neoadjuvant Bevacizumab.
Golshan M, Garber J, Gelman R, Tung N, Smith B, Troyan S, Greenberg C, Winer E, Ryan P. Surgical Complications and the Use of Neoadjuvant Bevacizumab. Cancer Research 2009, 69: 43-43. DOI: 10.1158/0008-5472.sabcs-09-43.Peer-Reviewed Original ResearchTriple-negative breast cancerDefinitive local therapyPhase II trialPostoperative complicationsNeoadjuvant cisplatinDefinitive surgeryII trialWound breakdownLocal therapyMedian ageBreast cancerSingle-arm phase II trialArm phase II trialTwo-sided Fisher's exact testClinical stage IIDose-dense ACSafety of bevacizumabOperable breast cancerBreast cancer surgerySingle-arm trialNegative breast cancerFisher's exact testCycles cisplatinNeoadjuvant bevacizumabNeoadjuvant setting
2008
Trends in Racial and Age Disparities in Definitive Local Therapy of Early-Stage Breast Cancer
Freedman RA, He Y, Winer EP, Keating NL. Trends in Racial and Age Disparities in Definitive Local Therapy of Early-Stage Breast Cancer. Journal Of Clinical Oncology 2008, 27: 713-719. PMID: 19103731, DOI: 10.1200/jco.2008.17.9234.Peer-Reviewed Original ResearchConceptsDefinitive local therapyBreast-conserving surgeryEarly-stage breast cancerLocal therapyBreast cancerHispanic womenStage I/II breast cancerEnd Results registry dataAsian womenReceipt of radiationMultivariate logistic regressionBreast cancer therapyRace/ethnicityMastectomy ratesTherapy ratesBreast conservationAdjusted analysisRegistry dataWomen 61Stage ITherapyAdult womenLogistic regressionCancerStudy period
2004
AN OVERVIEW OF CHEMOTHERAPY TRIALS IN LOCALIZED AND RECURRENT NONMETASTATIC PROSTATE CANCER
Oh W. AN OVERVIEW OF CHEMOTHERAPY TRIALS IN LOCALIZED AND RECURRENT NONMETASTATIC PROSTATE CANCER. Journal Of Urology 2004, 172: s34-s37. PMID: 15535440, DOI: 10.1097/01.ju.0000141674.92253.fe.Peer-Reviewed Original ResearchConceptsHormone refractory diseaseProstate cancerLocal therapyRefractory diseaseClinical trialsFeasibility of administering chemotherapyProstate cancer disease statesState of prostate cancerHormone refractory prostate cancerHigh riskDefinitive local therapyDefinitive local treatmentStudies evaluating chemotherapyRecurrent prostate cancerLocalized prostate cancerRefractory prostate cancerNonmetastatic prostate cancerPhase III trialsRisk of recurrenceCancer disease statesAndrogen-dependent diseasesMedline literature reviewAntigenic stateRandomized clinical trialsNeoadjuvant settingNeoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer
Nakabayashi M, Oh W. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Current Treatment Options In Oncology 2004, 5: 349-355. PMID: 15341673, DOI: 10.1007/s11864-004-0025-3.Peer-Reviewed Original ResearchConceptsHigh-risk localized prostate cancerLocalized prostate cancerLocally advanced prostate cancerHormone-refractory diseaseAdvanced prostate cancerProstate cancerAdjuvant chemotherapyLocal therapyTreatment of hormone-refractory prostate cancerHormone-refractory prostate cancerDefinitive local therapyDefinitive local treatmentImproved clinical benefitProspective randomized trialsRisk of recurrenceOptimal treatment strategyImproved survival ratesRandomized clinical trialsRadical prostatectomyChe-motherapySurvival benefitClinical benefitLocal treatmentChemotherapyNonrandomized trials
2003
Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints
Oh W. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urologic Oncology Seminars And Original Investigations 2003, 21: 229-234. PMID: 12810211, DOI: 10.1016/s1078-1439(03)00019-x.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAndrogen AntagonistsAndrogensAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkersChemotherapy, AdjuvantEstramustineFlutamideHumansLeuprolideMaleNeoadjuvant TherapyNeoplasms, Hormone-DependentPalliative CareProstatectomyProstatic NeoplasmsRandomized Controlled Trials as TopicRiskConceptsHigh-risk localized prostate cancerLocalized prostate cancerProstate cancerClinical parameters of efficacyNeoadjuvant androgen deprivation therapyManagement of localized diseaseDefinitive local therapyDefinitive local treatmentHormone-refractory settingAndrogen deprivation therapyRisk of recurrenceMolecular targeted therapyParameters of efficacyAndrogen-dependent diseasesDeprivation therapyNeoadjuvant therapyRadical prostatectomyLocal therapySystemic therapyLocalized diseaseClinical parametersRandomized studyLocal treatmentEarly diseaseTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply